Apogee Therapeutics (NASDAQ: APGE) saw its stock surge 28.80% in pre-market trading on Monday following the announcement of positive 16-week data from its Phase 2 APEX clinical trial. The trial evaluated APG777, the company's potentially best-in-class anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis.

The Phase 2 APEX trial met all primary and key secondary endpoints, exceeding trial objectives. APG777 demonstrated a 71.0% decrease from baseline in the Eczema Area Severity Index (EASI) at Week 16, significantly outperforming the placebo group's 33.8% reduction. Notably, 66.9% of participants treated with APG777 achieved EASI-75, the highest topline and placebo-adjusted efficacy of any biologic in a global study for atopic dermatitis. The drug also showed rapid onset of itch relief and was well-tolerated with a favorable safety profile consistent with other agents in its class.

These promising results position Apogee Therapeutics as a potential leader in the atopic dermatitis treatment market. The company plans to accelerate the readout of APEX Part B, testing higher exposures, to mid-2026, enabling a planned Phase 3 initiation in 2026. Additionally, Apogee has dosed its first patient in a head-to-head trial of APG279 (IL-13 + OX40L) versus DUPIXENT, with results expected in the second half of 2026. As Apogee advances its pipeline of optimized biologics for inflammatory and immunology indications, investors are showing increased confidence in the company's potential to deliver innovative treatments with improved efficacy and dosing regimens.